This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BG Medicine Announces Fiscal 2012 Second Quarter Results

Upcoming milestones include:

  • We expect our partner, Abbott, to obtain CE Mark and launch its automated version of the BGM Galectin-3 test in Europe.   
  • We expect to conclude one or more new distribution agreements to launch the BGM Galectin-3 test in additional important markets throughout the world.  
  • We expect final approval and pricing for the analyte-specific CPT code for the BGM Galectin-3 test, effective for the 2013 Clinical Laboratory Fee Schedule.   
  • We expect that the results and analysis of the BioImage study, which was used as the clinical validation study for the CardioSCORE test, will be presented at a major scientific conference.  
  • Finally, for the CardioSCORE test, we are continuing our discussions with the FDA and we look forward to providing an update on the expected timing for the re-filing of our 510(k), as well as our plans for the commercial launch of the product.

Financial Results

Three months ended   June 30, 2012

Product revenue for the quarter ended June 30, 2012 increased to $566,000 from $46,000 in the quarter ended June 30, 2011, reflecting increasing demand for the BGM Galectin-3 test. On a sequential quarterly basis, product revenue increased 36% to $566,000 from $416,000 in the quarter ended March 31, 2012. Service revenue decreased to $56,000 in the quarter ended June 30, 2012 from $175,000 in the corresponding period in 2011. Our service revenue consists primarily of activities under the HRP initiative. 

Research and development expenses for the quarter ended June 30, 2012 decreased to $2.1 million from $2.4 million in the quarter ended June 30, 2011. The decrease in expense was due to lower activity associated with the HRP initiative. On a sequential quarterly basis, research and development expenses decreased to $2.1 million from $3.0 million in the quarter ended March 31, 2012.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.77 -0.50%
FB $118.60 0.67%
GOOG $706.06 0.66%
YHOO $36.90 -0.11%
TSLA $212.06 0.25%


Chart of I:DJI
DOW 17,651.43 -9.28 -0.05%
S&P 500 2,041.82 -8.81 -0.43%
NASDAQ 4,690.20 -26.8940 -0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs